文献速递骨软组织肉瘤与黑色素瘤

标准剂量帕博利珠单抗联合减剂量伊匹木单抗治疗晚期黑色素瘤患者(KEYNOTE-029):一项开放标签1b期试验

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
PubMed 文献 · Lancet Oncol · 2017-07-17

这项开放标签1b期试验在澳大利亚、新西兰和美国的12个医疗中心纳入153例晚期黑色素瘤患者,评估标准剂量帕博利珠单抗联合减剂量伊匹木单抗的安全性和抗肿瘤活性。截至2016年10月17日,中位随访17.0个月,93例(61%,95%CI 53-69)达到客观缓解,1年无进展生存率估计为69%(95%CI 60-75),1年总生存率估计为89%(95%CI 83-93)。作者认为该方案毒性可控且抗肿瘤活性稳健,可能为耐受且有效的治疗选择,一项替代给药策略的随机2期试验正在进行中。

要点

  • 153例晚期黑色素瘤患者接受标准剂量帕博利珠单抗联合减剂量伊匹木单抗,客观缓解率为61%(95%CI 53-69)。
  • 69例(45%)发生110起3-4级治疗相关不良事件,无治疗相关死亡。
  • 估计1年无进展生存率为69%(95%CI 60-75),1年总生存率为89%(95%CI 83-93)。

核心结论

  • 标准剂量帕博利珠单抗联合四剂减剂量伊匹木单抗随后标准剂量帕博利珠单抗在晚期黑色素瘤患者中毒性可控且抗肿瘤活性稳健。
  • 这些数据提示标准剂量帕博利珠单抗联合减剂量伊匹木单抗可能为晚期黑色素瘤患者一种可耐受且有效的治疗选择。
  • 该联合方案替代给药策略的随机2期试验正在进行中。

研究设计与样本

  • 开放标签1b期试验,从澳大利亚、新西兰和美国的12个医疗中心招募患者。
  • 纳入年龄至少18岁、晚期黑色素瘤、东部肿瘤协作组体能状态0或1、按RECIST版本1.1有可测量病灶、器官功能充足、近期化疗毒性反应恢复至1级或以下、无需要全身类固醇或免疫抑制剂的活跃自身免疫病、无活跃非感染性肺炎、无未控制的甲状腺功能障碍或糖尿病、无活跃脑转移、未接受过免疫检查点抑制剂治疗的患者。
  • 患者接受静脉帕博利珠单抗2 mg/kg联合静脉伊匹木单抗1 mg/kg每3周一次共四剂,随后静脉帕博利珠单抗2 mg/kg每3周一次最长2年或直至疾病进展、不可耐受毒性、撤回知情同意或研究者决定。
  • 主要终点为安全性和耐受性;次要终点包括独立中心审查按RECIST版本1.1评估的客观缓解比例和总生存期,同时评估无进展生存期。
  • 主要终点在至少接受一剂联合治疗的所有患者中评估,活性在所有入组患者中评估;2015年1月13日至2015年9月17日入组并治疗153例患者。

主要发现

  • 截至2016年10月17日,中位随访17.0个月(IQR 14.8-18.8),153例患者中110例(72%)接受全部四剂帕博利珠单抗联合伊匹木单抗,64例(42%)继续帕博利珠单抗单药治疗。
  • 69例(45%)患者发生110起3-4级治疗相关不良事件,无治疗相关死亡。
  • 治疗相关不良事件导致22例(14%)患者停用帕博利珠单抗和伊匹木单抗,其中17例(11%)因同一事件停用两种治疗,5例(3%)因一个事件停用伊匹木单抗后因另一事件停用帕博利珠单抗;12例(8%)仅停用伊匹木单抗,14例(9%)仅停用帕博利珠单抗。
  • 92例(60%)患者发生158起任何级别的免疫介导不良事件,42例(27%)发生50起3-4级免疫介导不良事件;最常见的免疫介导不良事件为甲状腺功能减退(25例[16%])和甲状腺功能亢进(17例[11%])。
  • 93例(61%[95%CI 53-69])达到客观缓解;估计1年无进展生存率为69%(95%CI 60-75),估计1年总生存率为89%(95%CI 83-93)。

关键数值与推荐

  • 客观缓解:93/153例(61%,95%CI 53-69)。
  • 估计1年无进展生存率:69%(95%CI 60-75)。
  • 估计1年总生存率:89%(95%CI 83-93)。
  • 3-4级治疗相关不良事件:110起发生于69/153例(45%)。
  • 免疫介导不良事件:任何级别158起发生于92/153例(60%),3-4级50起发生于42/153例(27%)。

临床怎么用

  • 作者认为标准剂量帕博利珠单抗联合减剂量伊匹木单抗可能为晚期黑色素瘤患者一种可耐受且有效的治疗选择。
  • 该联合方案替代给药策略的随机2期试验正在进行中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab. METHODS: In this open-label, phase 1b trial, we recruited patients from 12 medical centres in Australia, New Zealand, and the USA. Eligible patients were aged at least 18 years, had advanced melanoma, had an Eastern Coooperative Oncology Group performance status of 0 or 1, had measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, had adequate organ function, had resolution of toxic effects of the most recent previous chemotherapy to grade 1 or less, had no active autoimmune disease requiring systemic steroids or immunosuppressive agents, had no active non-infectious pneumonitis, had no uncontrolled thyroid dysfunction or diabetes, had no active brain metastases, and had not received previous immune checkpoint inhibitor therapy. Patients received intravenous pembrolizumab 2 mg/kg plus intravenous ipilimumab 1 mg/kg every 3 weeks for four doses, followed by intravenous pembrolizumab 2 mg/kg every 3 weeks for up to 2 years or disease progression, intolerable toxicity, withdrawal of consent, or investigator decision. The primary endpoint was safety and tolerability. The proportion of patients achieving an objective response assessed per RECIST version 1.1 by independent central review and overall survival were secondary endpoints. We also assessed progression-free survival. The primary endpoint was assessed in all patients who received at least one dose of combination therapy. Activity was assessed in all enrolled patients. This trial is registered with ClinicalTrials.gov, number NCT02089685. Enrolment into this cohort is closed, but patients are still being monitored for safety and anti-tumour activity. FINDINGS: Between Jan 13, 2015, and Sept 17, 2015, we enrolled and treated 153 patients. As of the Oct 17, 2016, cutoff date, median follow-up was 17·0 months (IQR 14·8-18·8). 110 (72%) of 153 patients received all four pembrolizumab plus ipilimumab doses; 64 (42%) remained on pembrolizumab monotherapy. 110 grade 3-4 treatment-related adverse events occurred in 69 (45%) patients. No treatment-related deaths occurred. Treatment-related adverse events led to discontinuation of pembrolizumab and ipilimumab in 22 (14%) patients, including 17 (11%) who discontinued both treatments for the same event and five (3%) who discontinued ipilimumab for one event and later discontinued pembrolizumab for another. 12 (8%) patients discontinued ipilimumab only and 14 (9%) discontinued pembrolizumab only because of treatment-related adverse events. 158 immune-mediated adverse events of any grade occurred in 92 (60%) patients, and 50 immune-mediated adverse events of grade 3-4 occurred in 42 (27%) patients; the most common immune-mediated adverse events were hypothyroidism (25 [16%]) and hyperthyroidism (17 [11%]). 93 (61% [95% CI 53-69]) patients achieved an objective response. Estimated 1 year progression-free survival was 69% (95% CI 60-75), and estimated 1 year overall survival was 89% (95% CI 83-93). INTERPRETATION: Standard-dose pembrolizumab given in combination with four doses of reduced-dose ipilimumab followed by standard-dose pembrolizumab has a manageable toxicity profile and provides robust anti-tumour activity in patients with advanced melanoma. These data suggest that standard-dose pembrolizumab plus reduced-dose ipilimumab might be a tolerable, efficacious treatment option for patients with advanced melanoma. A randomised phase 2 trial of alternative dosing strategies of this combination is underway. FUNDING: Merck & Co, Inc.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017. PMID: 28729151. doi:10.1016/S1470-2045(17)30428-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。